Autolus

Cell and Gene
Share

Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities and capital required to manufacture, develop and commercialise its programmed T cell product candidates.

Autolus is a leader in T cell programing, underpinning the broad technology toolbox and manufacturing technology. Autolus is developing cancer therapies which we believe will offer patients substantial benefits over the existing standard of care.Autolus is a leader in T cell programing, underpinning the broad technology toolbox and manufacturing technology. Autolus is developing cancer therapies which we believe will offer patients substantial benefits over the existing standard of care. 

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.